JP7124234B2 - フェノルドパムの安定な局所用組成物 - Google Patents

フェノルドパムの安定な局所用組成物 Download PDF

Info

Publication number
JP7124234B2
JP7124234B2 JP2021553117A JP2021553117A JP7124234B2 JP 7124234 B2 JP7124234 B2 JP 7124234B2 JP 2021553117 A JP2021553117 A JP 2021553117A JP 2021553117 A JP2021553117 A JP 2021553117A JP 7124234 B2 JP7124234 B2 JP 7124234B2
Authority
JP
Japan
Prior art keywords
composition
fenoldopam
topical
topical composition
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515569A (ja
Inventor
シフリン，ヘレナ
シュライフェル，アレクサンドラ
ローゼンバーガー，ベレット
シュリンガー，ロン
シェスキン，ツヴィエル
アヴラモフ，アヴィ
Original Assignee
タロー・ファーマシューティカル・インダストリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タロー・ファーマシューティカル・インダストリーズ・リミテッド filed Critical タロー・ファーマシューティカル・インダストリーズ・リミテッド
Publication of JP2022515569A publication Critical patent/JP2022515569A/ja
Priority to JP2022127610A priority Critical patent/JP2022160648A/ja
Application granted granted Critical
Publication of JP7124234B2 publication Critical patent/JP7124234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021553117A 2019-03-08 2020-03-06 フェノルドパムの安定な局所用組成物 Active JP7124234B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022127610A JP2022160648A (ja) 2019-03-08 2022-08-10 フェノルドパムの安定な局所用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815893P 2019-03-08 2019-03-08
US62/815,893 2019-03-08
PCT/IB2020/051967 WO2020183322A1 (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022127610A Division JP2022160648A (ja) 2019-03-08 2022-08-10 フェノルドパムの安定な局所用組成物

Publications (2)

Publication Number Publication Date
JP2022515569A JP2022515569A (ja) 2022-02-18
JP7124234B2 true JP7124234B2 (ja) 2022-08-23

Family

ID=69846519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553117A Active JP7124234B2 (ja) 2019-03-08 2020-03-06 フェノルドパムの安定な局所用組成物
JP2022127610A Ceased JP2022160648A (ja) 2019-03-08 2022-08-10 フェノルドパムの安定な局所用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022127610A Ceased JP2022160648A (ja) 2019-03-08 2022-08-10 フェノルドパムの安定な局所用組成物

Country Status (11)

Country Link
US (2) US11446237B2 (https=)
EP (2) EP3908255B1 (https=)
JP (2) JP7124234B2 (https=)
CN (2) CN116966129A (https=)
AU (2) AU2020236525B2 (https=)
BR (1) BR112021017140A2 (https=)
CA (1) CA3131049A1 (https=)
ES (1) ES2941241T3 (https=)
IL (1) IL286197A (https=)
NZ (1) NZ781774A (https=)
WO (1) WO2020183322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023257375A1 (en) 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521324A (ja) 1998-07-24 2002-07-16 アルザ コーポレイション フェノルドパムの経皮投与のための配合物
US20110104287A1 (en) 2007-10-18 2011-05-05 Mia Levite Fenoldopam formulations and pro-drug derivatives
WO2016116909A2 (en) 2015-01-23 2016-07-28 Dr. Reddy's Laboratories Limited Non-staining topical gel compositions of nimesulide
WO2018042352A1 (en) 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE210975T1 (de) 1994-06-23 2002-01-15 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n- acetyl-l-cystein
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
AU3869399A (en) 1998-04-27 1999-11-16 Elan Pharmaceuticals, Inc. Transdermal administration of fenoldopam
JPH11335236A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 皮膚外用剤
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009502206A (ja) 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009076553A1 (en) 2007-12-11 2009-06-18 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2011144143A (ja) 2010-01-15 2011-07-28 Shiseido Co Ltd 皮膚外用剤
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
FR2991177B1 (fr) 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521324A (ja) 1998-07-24 2002-07-16 アルザ コーポレイション フェノルドパムの経皮投与のための配合物
US20110104287A1 (en) 2007-10-18 2011-05-05 Mia Levite Fenoldopam formulations and pro-drug derivatives
WO2016116909A2 (en) 2015-01-23 2016-07-28 Dr. Reddy's Laboratories Limited Non-staining topical gel compositions of nimesulide
WO2018042352A1 (en) 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders

Also Published As

Publication number Publication date
EP4218719A2 (en) 2023-08-02
EP3908255B1 (en) 2023-01-11
WO2020183322A1 (en) 2020-09-17
ES2941241T3 (es) 2023-05-19
JP2022160648A (ja) 2022-10-19
CN113543773B (zh) 2023-07-14
EP3908255A1 (en) 2021-11-17
BR112021017140A2 (pt) 2021-11-09
US20230059107A1 (en) 2023-02-23
AU2022202941A1 (en) 2022-05-26
EP4218719A3 (en) 2023-09-20
US11446237B2 (en) 2022-09-20
CN116966129A (zh) 2023-10-31
JP2022515569A (ja) 2022-02-18
AU2020236525B2 (en) 2022-02-03
CA3131049A1 (en) 2020-09-17
IL286197A (en) 2021-10-31
NZ781774A (en) 2023-03-31
CN113543773A (zh) 2021-10-22
AU2020236525A1 (en) 2021-11-04
US20220040089A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CA2977960C (en) Reduction of adipose tissue
JP6082158B2 (ja) ビマトプロストを含む局所用組成物及びそれを用いた育毛の刺激方法
EA038624B1 (ru) Фармацевтическая композиция для местного применения
AU2010253864A1 (en) Methods for administration and formulations for the treatment of regional adipose tissue
KR20250024093A (ko) 연성 항콜린제 유사체를 위한 제제
EP2303281B1 (en) Transdermal pharmaceutical compositions comprising danazol
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
JP7124234B2 (ja) フェノルドパムの安定な局所用組成物
US20210024636A1 (en) Compositions and methods for treating sexual dysfunction
TWI903311B (zh) 局部藥物組合物、其製備方法及其在醫藥上的用途
JP5033381B2 (ja) 外用医薬組成物
JP5460766B2 (ja) 外用医薬組成物
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
EP4268827A1 (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
US12233043B1 (en) Method of transdermal delivery of cannabinoid compositions
JPH111433A (ja) トルナフテ−ト含有液剤
TWI910890B (zh) 穩定性改善的苯酚衍生物的藥物組合物及其用途
WO2024013741A1 (en) Topical tapinarof composition for treating skin disorders
CN121969376A (zh) 用于治疗痤疮样皮疹的皮甾酮-17α-丙酸酯
TW202519237A (zh) 用於治療痤瘡樣疹之皮甾酮-17α-丙酸酯
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210922

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220810

R150 Certificate of patent or registration of utility model

Ref document number: 7124234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150